NEW YORK (GenomeWeb) – Investment firm ViaLogy today announced it is acquiring UK molecular diagnostics firm Premaitha Health for £10.5 million ($17.8 million) in a reverse takeover.

ViaLogy will take on the Premaitha Health name with its shares to begin trading on the London Stock Exchange's AIM market next month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.